Related Experiment Video
Updated: Jun 8, 2026

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
Relationship between (123)I-MIBG scintigrams and REM sleep behavior disorder in Parkinson's disease
Takashi Nomura1, Yuichi Inoue, Birgit Högl
1Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Japan. ntnomura@med.tottori-u.ac.jp
Background:
Uptake of (123)I-labeled meta-iodobenzylguanidine (MIBG) in myocardial scintigrams has been shown to be as low in patients with idiopathic RBD as in Parkinson's disease (PD) patients. AIM FOR STUDY: To clarify whether the existence of RBD accelerates autonomic dysfunction in PD, we investigated the association between MIBG scintigraphic findings and RBD measures among non-dementia PD patients.
Subjects & Methods:
We conducted clinical interviews to assess REM sleep behavior disorder (RBD) symptoms, and performed polysomnograms (PSG) recordings and MIBG scintigrams on 49 PD patients. The patients were divided into three groups (PD with clinical RBD, PD with subclinical RBD, and PD with normal REM sleep).
Results:
PD patients with clinical RBD had reduced MIBG uptake as determined by heart-to-mediastinum ratios of the delayed image compared to those with subclinical RBD and those with normal REM sleep. Multiple linear regression analysis revealed that only the existence of RBD symptoms was significantly associated with reduced MIBG uptake among PD patients without dementia after adjusting for demographic and PD symptom-related variables.
Conclusion:
PD patients with clinical RBD might suffer from a wider α-synuclein pathology, including reduced cardiac sympathetic ganglia function as reflected by a lowered MIBG uptake.
Insights
Patients with Parkinson's disease (PD) and REM sleep behavior disorder (RBD) show reduced cardiac MIBG uptake, indicating accelerated autonomic dysfunction. This suggests a broader alpha-synuclein pathology in PD patients with RBD.
Area of Science:
- Neurology
- Cardiology
- Sleep Medicine
Background:
- Reduced cardiac uptake of 123I-labeled meta-iodobenzylguanidine (MIBG) is observed in idiopathic REM sleep behavior disorder (RBD) and Parkinson's disease (PD).
- Autonomic dysfunction is a common feature in PD, and its progression may be influenced by comorbid RBD.
Purpose of the Study:
- To investigate the association between MIBG scintigraphic findings and RBD severity in non-dementia PD patients.
- To determine if RBD accelerates autonomic dysfunction in Parkinson's disease.
Main Methods:
- Clinical interviews and polysomnograms (PSG) were used to assess RBD symptoms in 49 PD patients.
- MIBG scintigraphy was performed to evaluate cardiac sympathetic nerve function.
- Patients were categorized into three groups: PD with clinical RBD, PD with subclinical RBD, and PD with normal REM sleep.
Main Results:
- PD patients with clinical RBD exhibited significantly lower MIBG uptake (heart-to-mediastinum ratio) compared to those with subclinical RBD or normal REM sleep.
- Multiple linear regression analysis confirmed that RBD symptoms were the sole significant predictor of reduced MIBG uptake in PD patients without dementia, after adjusting for covariates.
- These findings highlight a correlation between RBD and impaired cardiac sympathetic innervation in PD.
Conclusions:
- Clinical RBD in PD patients is associated with reduced cardiac sympathetic ganglia function, as indicated by lower MIBG uptake.
- This suggests that RBD may be linked to a more widespread alpha-synuclein pathology in Parkinson's disease.
- Early identification of RBD in PD patients could aid in predicting autonomic dysfunction progression.
Related Concept Videos
REM Sleep Behavior Disorder
RBD is significantly associated with...
Management of Insomnia
Parkinson Disease l: Introduction
Alterations in Muscle Tone lll
